

**Performance Report**

Entity Name	<i>Te Pūao Mātai Pukupuku New Zealand Society for Oncology Incorporated</i>
For the year ended	<i>31/12/2025</i>
Rounded to	<i>nearest dollar</i>

**Entity information**

Name of entity	<i>Te Pūao Mātai Pukupuku New Zealand Society for Oncology Incorporated</i>
Entity identifier	<i>CC3463</i>
Type of entity	<i>Incorporated Society and Registered Charity</i>
Entity's purpose or mission	<i>To improve the lives of people with cancer today and reduce the impact of cancer tomorrow through translational research. To bring together Cancer Care Professionals &amp; Cancer Researchers, including an Annual Conference. To achieve equity, and to support advocacy, education and the advancement of knowledge in all aspects of oncology.</i> <i>Any income, benefit, or advantage must be used to advance the charitable purposes of the Society.</i>
Entity structure	<i>The entire management of the Society and its property shall be vested with an Executive Committee consisting of a President, Vice President, Secretary/Treasurer and officers. The Executive Committee shall include the immediate past Convenor of the Annual Meeting and the Convenor of the next Annual Meeting.</i>
Entity's governance arrangements	<i>The entire management of the Society and its property shall be vested with an Executive Committee consisting of a President, Vice President, Secretary/Treasurer and officers. The Executive Committee shall include the immediate past Convenor of the Annual Meeting and the Convenor of the next Annual Meeting.</i>
Other entities controlled by the entity	<i>None</i>
Entity's reliance on volunteers and donated goods or services	<i>None, except for Executive Committee members giving their time</i>

**Performance Report**

Entity Name	<i>Te Pūao Mātai Pukupuku New Zealand Society for Oncology Incorporated</i>
For the year ended	<i>31/12/2025</i>
Rounded to	<i>nearest dollar</i>

**Statement of Service Performance****Description of medium to long term objectives**

*The Society's medium to long term objectives is to support translational cancer research across Cancer Care professionals and cancer researchers through providing our ASM, as well as any other additional meetings or opportunities the membership requests.*

Description of significant activities	Quantity	
	Current year	Last year
Annual Scientific Meeting	1	1
Roche Translational Award (\$40k)	2	1
SIG Meetings	4	3

**Performance Report**

Entity Name

*Te Pūao Mātai Pukupuku New Zealand Society for Oncology Incorporated*

For the year ended

*31/12/2025*

Rounded to

*nearest dollar***FINANCIAL INFORMATION****Statement of financial performance**

	Note	Current year \$	Last year \$
<b>Revenue</b>			
Donations, koha, bequests and other general fundraising activities		-	-
General grants		46,000	46,000
Membership fees and subscriptions	1	6,110	8,640
Gross sales from society activities		48,110	20,415
Interest, dividends and other investment revenue		4,094	3,540
Other revenue		23,115	10,076
<b>Total revenue</b>		<b>127,429</b>	<b>88,671</b>
<b>Expenses</b>			
Employee remuneration and other related expenses		33,079	23,027
Expenses related to society activities		12,955	15,571
Grants and donations paid		103,000	8,000
Other expenses		14,683	7,817
<b>Total expenses</b>		<b>163,717</b>	<b>54,415</b>
<b>Surplus/(Deficit)</b>		<b>(36,288)</b>	<b>34,256</b>

RP.

**Performance Report**

Entity Name

Te Pūao Mātai Pukupuku New Zealand Society for Oncology Incorporated

For the year ended

31/12/2025

Rounded to

nearest dollar

**FINANCIAL INFORMATION**  
Statement of financial position


	Note	Current year \$	Last year \$
<b>Assets</b>			
<b>Current assets</b>			
Cash and short-term deposits		95,659	131,947
Debtors and prepayments	3	-	-
Inventory		-	-
<b>Total current assets</b>		<b>95,659</b>	<b>131,947</b>
<b>Non-current assets</b>			
Property, plant and equipment	5	-	-
Investments	6	-	-
<b>Total non-current assets</b>		<b>-</b>	<b>-</b>
<b>Total assets</b>		<b>95,659</b>	<b>131,947</b>
<b>Liabilities</b>			
<b>Current Liabilities</b>			
Bank overdraft		-	-
Creditors and accrued expenses	4	-	-
Employee costs payable		-	-
Deferred revenue		-	-
<b>Total current liabilities</b>		<b>-</b>	<b>-</b>
<b>Non-current liabilities</b>			
Loans	4	-	-
<b>Total non-current liabilities</b>		<b>-</b>	<b>-</b>
<b>Total Liabilities</b>		<b>-</b>	<b>-</b>
<b>Net assets (total assets less total liabilities)</b>		<b>95,659</b>	<b>131,947</b>
<b>Accumulated Funds</b>			
Capital contributed by owners		-	-
Accumulated surpluses or (deficits)	7	95,659	131,947
Restricted and discretionary reserves		-	-
Property, plant and equipment revaluation reserve		-	-
Investment revaluation reserve		-	-
Other reserves		-	-
<b>Total Accumulated Funds</b>		<b>95,659</b>	<b>131,947</b>

This performance report has been approved by those charged with governance.

Date

15 May 2026

Signature



Name

Cameron Montague-Ebbs

Position

Treasurer

Date

14 May 2026

Signature



Name

Rachel Purcell

Position

President

**Performance Report**

Entity Name

Te Pūao Mātai Pukupuku New Zealand Society for Oncology Incorporated

For the year ended

31/12/2025

Rounded to

nearest dollar

**FINANCIAL INFORMATION****Statement of cash flows**

	Current year \$	Last year \$
<b>Cash flows from operating activities</b>		
<b>Cash received:</b>		
Donations, koha, bequests and other general fundraising activities	-	-
General grants	46,000	46,000
Membership fees and subscriptions	6,110	8,640
Gross sales from society activities	48,110	20,415
Interest, dividends and other investment receipts	4,094	3,540
<u>Other cash received</u>	23,115	10,076
<b>Total receipts</b>	<b>127,429</b>	<b>88,671</b>
<b>Cash payments:</b>		
Employee remuneration and other related payments	33,079	23,027
Expenses related to society activities	12,955	15,571
Grants and donations paid	103,000	8,000
<u>Other payments</u>	14,683	7,817
<b>Total payments</b>	<b>163,717</b>	<b>54,415</b>
<b>Net cash flows from operating activities</b>	<b>(36,288)</b>	<b>34,256</b>
<b>Cash flows from other activities</b>		
<b>Cash received:</b>		
Sale of property, plant and equipment	-	-
Sale of investments	-	-
Cash received from loans from other parties	-	-
Cash received from owners (capital contributions)	-	-
<b>Cash payments:</b>		
Payments to acquire property, plant and equipment	-	-
Payments to purchase investments	-	-
Repayments of loans from other parties	-	-
Capital distributed to owners	-	-
<b>Net cash flows from other activities</b>	<b>-</b>	<b>-</b>
<b>Net increase/(decrease) in cash</b>	<b>(36,288)</b>	<b>34,256</b>
<b>Opening cash</b>	<b>131,947</b>	<b>97,691</b>
<b>Closing cash</b>	<b>95,659</b>	<b>131,947</b>

**Performance Report**

Entity Name

Te Pūao Mātai Pukupuku New Zealand Society for Oncology Incorporated

For the year ended

31/12/2025

Rounded to

nearest dollar

**Statement of Accounting Policies**

**Basis of preparation**

This performance report is prepared in accordance with the XRB's Tier 3 (NFP) Standard. The entity is eligible to apply these requirements as it does not have public accountability and has total annual expenses of less than \$5million. All transactions in the performance report are reported using the accrual basis of accounting. This performance report is prepared under the assumption that the entity is a going concern and will continue to operate for the foreseeable future.

**Treatment of GST**

The entity is registered for GST and all amounts are recorded on a GST exclusive basis, except for Debtors and Creditors which are stated inclusive of GST

**Income Tax**

Te Pūao Mātai Pukupuku New Zealand Society for Oncology Incorporated is wholly exempt from New Zealand income tax having fully complied with all statutory conditions for these exemptions.

**Cash and short-term deposits**

Cash and short-term deposits in the Statement of Financial Position and Statement of Cash Flows comprise cash balances and bank balances (including short-term deposits) with original maturities of 365 days or less.

**[Specific Accounting Policy for the entity's significant transactions or balances]**

**[Specific Accounting Policy for the entity's significant transactions or balances]**

**Tier 2 PBE Accounting Standards Applied (if any)**

**Changes in Accounting Policies**

There have been no changes in accounting policies during the financial year 2025

RP

**Performance Report**

Entity Name	Te Pūao Mātai Pukupuku New Zealand Society for Oncology Incorporated
For the year ended	31/12/2025
Rounded to	nearest dollar

**Note 1 - Analysis of Revenue**

Category	Analysis	Current year	Last year
Interest, dividends and other investment revenue	Bank dividends/interest	1,143	
	Short Term deposit interest	2,951	
	2025 Tier 4 reporting		3,540
	<b>Total</b>	<b>4,094</b>	<b>3,540</b>

Category	Analysis	Current year	Last year
General grants	Roche Award	46,000	46,000
	<b>Total</b>	<b>46,000</b>	<b>46,000</b>

Category	Analysis	Current year	Last year
Other revenue	IRD GST Refund	5,473	
	ESMO Dispersment	17,642	
	2025 Tier 4 reporting		10,076
	<b>Total</b>	<b>23,115</b>	<b>10,076</b>

Category	Analysis	Current year	Last year
Membership fees and subscriptions	Total Membership fees for 2025	6,110	
	2025 Tier 4 reporting		8,640
	<b>Total</b>	<b>6,110</b>	<b>8,640</b>

Category	Analysis	Current year	Last year
Revenue from commercial activities	SIG meetings	2,196	
	Coffee cart purchase	3,450	
	Surplus from conference	42,464	
	2025 Tier 4 reporting		20,415
	<b>Total</b>	<b>48,110</b>	<b>20,415</b>

RP

**Performance Report**

Entity Name	Te Pūao Mātai Pukupuku New Zealand Society for Oncology Incorporated
For the year ended	31/12/2025
Rounded to	nearest dollar

**Note 2 - Analysis of Expenses**

Category	Analysis	Current year	Last year
Expenses related to fundraising	N/A		N/A
<b>Total</b>		-	

Category	Analysis	Current year	Last year
Employee remuneration and other related expenses	Employee	33,079	
	2025 Tier 4 reporting		23,027
<b>Total</b>		33,079	23,027

Category	Analysis	Current year	Last year
Expenses related to commercial activities	Coffee cart	3,450	N/A
	Conference related costs	6,525	
	CI fees	2,250	
	SIG meeting fees	730	
	2025 Tier 4 reporting		15,571
<b>Total</b>		12,955	15,571

Category	Analysis	Current year	Last year
Other expenses	ESMO Dispersment	9,618	N/A
	Logo	1,000	
	XERO	483	
	DIA Charities	51	
	GST	2,893	
	SIG	631	
	Bank fees	7	7,817
	<b>Total</b>		14,683

Category	Analysis	Current year	Last year
Grants and donations made	Roche 2024 & 2025	92,000	N/A
	Travel Award NZSO2025	8,000	
	CRTNZ Award	3,000	
	2025 Tier 4 reporting		8,000
<b>Total</b>		103,000	8,000

RP

**Performance Report**

Entity Name	Te Pūao Mātai Pukupuku New Zealand Society for Oncology Incorporated
For the year ended	31/12/2025
Rounded to	nearest dollar

**Note 3 - Analysis of Assets**

Category	Analysis	Current year	Last year
Cash and short-term deposits	Cash	33,876	73,114
	Term Deposits	61,783	58,833
<b>Total</b>		<b>95,659</b>	<b>131,947</b>

Category	Analysis	Current year	Last year
Debtors and prepayments	N/A		
<b>Total</b>		<b>-</b>	<b>-</b>

Category	Analysis	Current year	Last year
Inventory	N/A		
<b>Total</b>		<b>-</b>	<b>-</b>

RP

**Performance Report**

Entity Name	Te Pūao Mātai Pukupuku New Zealand Society for Oncology Incorporated
For the year ended	31/12/2025
Rounded to	nearest dollar

**Note 4 - Analysis of Liabilities**

Category	Analysis	Current year	Last year
Creditors and accrued expenses	N/A		
<b>Total</b>		-	-

Category	Analysis	Current year	Last year
Employee costs payable	N/A		
<b>Total</b>		-	-

Category	Analysis	Current year	Last year
Deferred revenue	N/A		
<b>Total</b>		-	-

Category	Analysis	Current year	Last year
Loans	N/A		
<b>Total</b>		-	-

RP

**Performance Report**

Entity Name

Te Pūao Mātai Pukupuku New Zealand Society for Oncology Incorporated

For the year ended

31/12/2025

Rounded to

nearest dollar

**Note 5 - Property, Plant and Equipment**

Asset Class	Current year					
	Opening Carrying Amount	Purchases	(Disposals)	(Depreciation and Impairment)	Revaluation Movements	Closing Carrying amount
Land	N/A	-	-	-	-	-
Buildings	N/A	-	-	-	-	-
Motor vehicles	N/A	-	-	-	-	-
Furniture and fixtures	N/A	-	-	-	-	-
Office equipment	N/A	-	-	-	-	-
Computers	N/A	-	-	-	-	-
Machinery	N/A	-	-	-	-	-
<b>Total</b>	-	-	-	-	-	-

Asset Class	Last year					
	Opening Carrying Amount	Purchases	(Disposals)	(Depreciation and Impairment)	Revaluation Movements	Closing Carrying amount
Land	N/A	-	-	-	-	-
Buildings	N/A	-	-	-	-	-
Motor vehicles	N/A	-	-	-	-	-
Furniture and fixtures	N/A	-	-	-	-	-
Office equipment	N/A	-	-	-	-	-
Computers	N/A	-	-	-	-	-
Machinery	N/A	-	-	-	-	-
<b>Total</b>	-	-	-	-	-	-

**Source and Date of Valuation for Assets (including significant donated assets recorded at valuation)**

Description of Asset	Source of Valuation	Date of Valuation	Amount
N/A			

**Significant Donated Assets and Heritage Assets Not Recorded**

N/A

RP

**Performance Report**

Entity Name

For the year ended

Rounded to

Te Pūao Mātai Pukupuku New Zealand Society for Oncology Incorporated

31/12/2025

nearest dollar

**Note 6 - Investments**

Asset Class	Valuation Method	Current year					Gains/(Losses) on revaluation or (Impairment)	Closing Carrying amount
		Opening Carrying Amount	Purchases	(Disposals)	Income reinvested			
N/A	Current Market Value	-	-	-	-	-	-	
	Current Market Value	-	-	-	-	-	-	
	Current Market Value	-	-	-	-	-	-	
	Cost less Impairment	-	-	-	-	-	-	
	Cost less Impairment	-	-	-	-	-	-	
	Cost less Impairment	-	-	-	-	-	-	
<b>Total</b>		-	-	-	-	-	-	

Asset Class	Valuation Method	Last Year					Gains/(Losses) on revaluation or (Impairment)	Closing Carrying amount
		Opening Carrying Amount	Purchases	(Disposals)	Income reinvested			
N/A	Current Market Value	-	-	-	-	-	-	
	Current Market Value	-	-	-	-	-	-	
	Current Market Value	-	-	-	-	-	-	
	Cost less Impairment	-	-	-	-	-	-	
	Cost less Impairment	-	-	-	-	-	-	
	Cost less Impairment	-	-	-	-	-	-	
<b>Total</b>		-	-	-	-	-	-	

Source and Date of Valuation for each Class of Investments Recorded at Current Market Value		
Asset class	Source of Valuation	Date of Valuation
N/A		

RP

**Performance Report**

Entity Name

Te Pūao Mātai Pukupuku New Zealand Society for Oncology Incorporated

For the year ended

31/12/2025

Rounded to

nearest dollar

**Note 7 - Accumulated Funds**

Description	Current year						Total
	Capital Contributed by Owners	Accumulated Surpluses or Deficits	Restricted and Discretionary Reserves	Property, Plant and Equipment Revaluation Reserves	Investment Revaluation Reserves	Other Reserves	
Opening balance	-	131,947	-	-	-	-	131,947
Capital contributed by owners	N/A						-
Capital returned to owners	N/A						-
Surplus/(Deficit)		(36,288)					(36,288)
Distributions paid to owners		N/A					-
Transfer to restricted or discretionary reserves		N/A	N/A				-
Transfer from restricted or discretionary reserves		N/A	N/A				-
Revaluation movements				N/A	N/A		-
Transfers from revaluation reserve due to disposal of assets		N/A		N/A	N/A		-
Other movements recognised directly in accumulated funds						N/A	-
<b>Closing balance</b>	-	<b>95,659</b>	-	-	-	-	<b>95,659</b>

Description	Last year						Total
	Capital Contributed by Owners	Accumulated Surpluses or Deficits	Restricted and Discretionary Reserves	Property, Plant and Equipment Revaluation Reserves	Investment Revaluation Reserves	Other Reserves	
Opening balance	N/A	97,691	N/A	N/A	N/A	N/A	97,691
Capital contributed by owners	-						-
Capital returned to owners	-						-
Surplus/(Deficit)		34,256					34,256
Distributions paid to owners		-					-
Transfer to restricted or discretionary reserves		-	-				-
Transfer from restricted or discretionary reserves		-	-				-
Revaluation movements				-	-		-
Transfers from revaluation reserve due to disposal of assets		-		-	-		-
Other movements recognised directly in accumulated funds		-					-
<b>Closing balance</b>	-	<b>131,947</b>	-	-	-	-	<b>131,947</b>

**Breakdown of Restricted and Discretionary Reserves**

Name	Nature and Purpose	Current year	Last year
		\$	\$
N/A			
	<b>Total</b>	-	-

**Commitments**

There are no commitments as at balance date 31/12/2025

RP -

**Performance Report**

Entity Name	<i>Te Pūao Mātai Pukupuku New Zealand Society for Oncology Incorporated</i>
For the year ended	<i>31/12/2025</i>
Rounded to	<i>nearest dollar</i>

**Contingent Liabilities and Guarantees**

There are no contingent liabilities or guarantees as at balance date 31/12/2025

RP

**Performance Report**

Entity Name	Te Pūao Mātai Pukupuku New Zealand Society for Oncology Incorporated
For the year ended	31/12/2025
Rounded to	nearest dollar

**Note 9 - Deferred Revenue**

Description	Purpose and nature of the documented expectations over future use	Date documented expectations are expected to be satisfied	Original Amount \$	Deferred Amount	
				Current year \$	Last year \$
N/A	N/A	N/A			
<b>Total</b>			-	-	-

**Note 10 - Goods or services provided in kind to the entity**

Description	Amount \$
N/A	

**Note 11 - Assets used as security for liabilities**

Description of borrowing	Description of asset used security	Amount of borrowing	Amount of asset used as security
N/A	N/A		

**Note 12 - Assets held on behalf of others**

Description of the assets held	Name of entity on whose behalf assets are held
N/A	N/A

RP

**Performance Report**

Entity Name	Te Pūao Mātai Pukupuku New Zealand Society for Oncology Incorporated
For the year ended	31/12/2025
Rounded to	nearest dollar

**Note 13 - Related Party Transactions**

Description of related party relationship	Description of the Transactions	Value of Transactions		Amount owing from/(to) related party	
		Current Year \$	Last Year \$	Current Year \$	Last Year \$
N/A	N/A				

*OR (if not applicable to the entity, you may choose to disclose the below)*

There were no significant transactions, or any other transactions requiring disclosure, involving related parties during the financial year ending 31/12/2025

**Note 14 - Events After the Balance Date**

Nature of the Event	Estimate of the financial effect	Effect, if any on the entity's ability to continue operating
N/A	N/A	N/A

*OR (if not applicable to the entity, you may choose to disclose the below)*

There were no events that have occurred after the balance date that would have a material impact on the Performance Report ending 31/12/2025.

**Note 15 - Ability to Continue Operating**

We have all intentions to continue operating in the 2026 Financial Year

**Note 16 - Correction of Errors**

This is the first year of reporting on Tier 3, previously have been reporting on Tier 4. No corrections to note from last year.

RP